# Oral Dosage Form New Animal Drugs; Milbemycin Oxime, Lufenuron, and Praziquantel
> **Food and Drug Administration** · Final rule. · Published 2012-01-27 · Effective 2012-01-27 · 77 FR 4225
## Document
- **Document number:** 2012-1744
- **Category:** other
- **Sub-agency:** Food and Drug Administration
- **Federal Register citation:** 77 FR 4225
- **CFR reference:** 21 CFR 520
- **Publication date:** 2012-01-27
- **Effective date:** 2012-01-27
- **HHS docket:** Docket No. FDA-2011-N-0003
## Abstract

The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a new animal drug application (NADA) filed by Novartis Animal Health US, Inc. The NADA provides for the veterinary prescription use of milbemycin oxime, lufenuron, and praziquantel for the prevention of heartworm disease, for prevention and control of fleas, and for the treatment and control of various internal parasites in dogs.

## Source
- [Federal Register document](https://www.federalregister.gov/documents/2012/01/27/2012-1744/oral-dosage-form-new-animal-drugs-milbemycin-oxime-lufenuron-and-praziquantel)
---
*AI Analytics · CC0 1.0*